Induction of apoptosis by the kinase inhibitor flavopiridol in human ovarian cancer cell lines.
10.3802/kjgo.2008.19.1.26
- Author:
Soo Young HUR
1
;
Joon Mo LEE
Author Information
1. Department of Obstetrics and Gynecology, College of Medicine, The Catholic University of Korea, Seoul, Korea. leejm@catholic.ac.kr
- Publication Type:In Vitro ; Original Article
- Keywords:
Flavopiridol;
Ovarian cancer cell lines;
Apoptosis
- MeSH:
Apoptosis;
Blotting, Western;
Caspase 3;
Cell Cycle Checkpoints;
Cell Line;
Cell Line, Tumor;
Cell Survival;
Flavonoids;
Humans;
In Situ Nick-End Labeling;
Ovarian Neoplasms;
Phosphotransferases;
Piperidines;
Proteins;
Strikes, Employee
- From:Korean Journal of Gynecologic Oncology
2008;19(1):26-39
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
OBJECTIVE: Flavopiridol that inhibits cyclin-dependent kinase, can cause cell cycle arrest, induce apoptosis in human tumor cell lines. In the present study, we investigated apoptotic effects of flavopiridol and the underlying molecular mechanisms in human ovarian cancer cell lines. METHODS: We used TOV-21G and TOV-112D cell lines. The cell viability was tested by MTT assay and apoptosis was assessed by TUNEL assay and annexin-V binding. Western blot was used to examine apoptosis related protein levels. MAP kinase activity was analyzed by non-radioactive MAP kinase assay kit. RESULTS: Treatment of TOV-21G and TOV-112D cells with flavopiridol (50 nM to 1000 nM) led to a dose- and time-dependent inhibition of cell growth and survival. Dose-related induction of apoptosis was also observed in these cell lines. Flavopiridol (500 nM) induced striking decreases in the levels of the antiapoptic proteins Mcl-1, Bcl-X(L), and XIAP in both cell lines. In contrast, expression of Bax, Bcl-2, and AIF was not significantly influenced by flavopiridol. Although flavopiridol resulted in accumulation of p53 in both cells, flavopiridol mediated apoptosis was p53 independent because it occurred to the same degree in TOV-112D cells in which p53 was inactivated by mutation. Flavopiridol treatment resulted in enhanced cleavage of pro-caspase 9 and activation of caspase 3. Apoptosis was associated with suppression of ERK activity. CONCLUSION: Although the precise mechanisms of flavopiridol mediated cytotoxicity have not been fully defined, these data suggest that flavopiridol has activity against ovarian cancers in vitro and is worthy of continued clinical development in the treatment of ovarian cancer.
